Treatment of Kratom Withdrawal
For moderate to severe kratom withdrawal, initiate buprenorphine-naloxone at 4-8 mg sublingual based on withdrawal severity, with dosing correlated to the amount of kratom used daily (patients using <20g/day typically need 4-8mg, while those using >40g/day may require 12-16mg daily). 1
Understanding Kratom Withdrawal
Kratom's active alkaloids (mitragynine and 7-hydroxymitragynine) act as partial mu-opioid receptor agonists, producing opioid-like dependence and withdrawal symptoms that meet DSM-5 criteria for opioid use disorder 2. The withdrawal syndrome presents with:
Psychological symptoms:
- Depressed mood, anxiety, restlessness
- Irritability, feeling tense
- Cravings and loss of concentration
Physical symptoms:
- Myalgia, joint pain, tremors
- Lacrimation, rhinorrhea, yawning
- Insomnia, diarrhea, chills
- Feverish sensation, loss of appetite
- Itching, sweating 2
Critical caveat: Semisynthetic kratom derivatives like mitragynine pseudoindoxyl (MP) produce rapid-onset, severe withdrawal that is more intense than traditional kratom powder 3. These patients may present with Clinical Opiate Withdrawal Scale (COWS) scores >30 and require more aggressive management.
Treatment Algorithm
Step 1: Assess Withdrawal Severity
Use the COWS score to stratify treatment:
- Mild withdrawal (COWS <8): Symptomatic management may suffice
- Moderate to severe (COWS ≥8): Medication-assisted treatment indicated 4
Confirm time since last kratom use (typically >12 hours for withdrawal to manifest, similar to short-acting opioids) 4.
Step 2: Choose Treatment Approach
Primary Option - Buprenorphine-Naloxone (Preferred):
The evidence strongly supports buprenorphine as the most effective treatment 1, 2. Dosing is directly correlated with daily kratom consumption:
- Low users (<20g/day): Start 4-8 mg sublingual
- Moderate users (20-40g/day): Start 8-12 mg sublingual
- Heavy users (>40g/day): Start 12-16 mg sublingual 1
Initiation protocol:
- Give initial dose of 4-8 mg sublingual based on withdrawal severity
- Reassess after 30-60 minutes
- Target total first-day dose of 8-16 mg for most patients
- Continue daily dosing, adjusting based on response
- Unlike opioid use disorder treatment, consider divided dosing (3-4 times daily) for analgesia if pain is prominent 5
The correlation coefficient between kratom dose and required buprenorphine dose is 0.84, indicating a strong linear relationship 1.
Alternative Option - Methadone:
Recent evidence shows methadone is well-tolerated and effective for kratom use disorder 6:
- Mean starting dose: 27.5 mg (range 15-30 mg)
- Mean maintenance dose: 98.6 mg (range 35-190 mg)
- 93% treatment retention in case series
- Consider for patients who cannot tolerate or fail buprenorphine
Symptomatic Management (Mild Cases or Adjunctive):
Based on opioid withdrawal treatment principles 4:
- α2-agonists: Clonidine 0.1-0.2 mg every 6-8 hours (avoid if hypotensive) or lofexidine
- Antiemetics: Promethazine or ondansetron for nausea/vomiting
- Benzodiazepines: For anxiety, muscle cramps, and catecholamine surge
- Antidiarrheals: Loperamide for diarrhea
- Gabapentin: 300-900 mg three times daily for anxiety and restlessness
- Hydroxyzine: For anxiety and insomnia 7
One case successfully used symptom-triggered clonidine with scheduled hydroxyzine 7, while another used dihydrocodeine with lofexidine 8.
Step 3: Severe Withdrawal Management
For patients with severe withdrawal (COWS >25-30), particularly those using high-potency derivatives like MP 3:
- Hospitalize for monitoring
- Aggressive symptomatic management over 72-96 hours
- Clonidine, hydroxyzine, gabapentin, loperamide, antiemetics
- Blood pressure and vital sign monitoring (expect hypertension, tachycardia)
- Consider buprenorphine if not already initiated
Step 4: Transition and Maintenance
After acute withdrawal resolution:
- Continue buprenorphine maintenance therapy (typically 8-16 mg daily)
- Arrange addiction medicine follow-up within 3-7 days
- Consider naltrexone (including extended-release Vivitrol) once opioid-free interval established 3
- Naltrexone does NOT precipitate withdrawal after kratom cessation, unlike with full opioid agonists 3
Critical Clinical Pitfalls
1. Underestimating withdrawal severity: Kratom withdrawal can be as severe as traditional opioid withdrawal, especially with high-potency derivatives. Don't dismiss patient distress 3, 2.
2. Inadequate buprenorphine dosing: The strong correlation between kratom dose and buprenorphine requirement means heavy users need higher doses. Starting too low leads to treatment failure 1.
3. Missing semisynthetic derivatives: Patients using 7-hydroxymitragynine or mitragynine pseudoindoxyl tablets experience more severe, rapid-onset withdrawal than traditional kratom powder users 3.
4. Standard toxicology limitations: Kratom and its derivatives are not detected on routine urine drug screens. Diagnosis relies on history 3.
5. Precipitated withdrawal concerns: Unlike with full opioid agonists, buprenorphine initiation for kratom withdrawal does not typically precipitate severe withdrawal, as kratom alkaloids are partial agonists 1.
6. Perinatal considerations: Pregnant patients with kratom use disorder can develop neonatal withdrawal symptoms (oral intolerance, restlessness, irritability, vomiting). Buprenorphine is appropriate but requires collaborative obstetric care 2, 9.
Special Populations
Pregnant patients: Buprenorphine is supported for treatment, though evidence is limited to case reports. Collaborative care with obstetrics is essential 9.
Patients with concurrent substance use: Address polysubstance use. One case report described severe kava withdrawal requiring phenobarbital in addition to buprenorphine for kratom 10.